Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Vafidemstat - Oryzon Genomics

Next Previous
X
Search
Drug Profile

Vafidemstat - Oryzon Genomics

Alternative Names: ORY-2001

Latest Information Update: 06 Dec 2024

Price :

$50 *

Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Oryzon
  • Developer Institute of Medical and Molecular Genetics; Oryzon
  • Class Amines; Antidementias; Antiparkinsonians; Antipsychotics; Behavioural disorder therapies; Cyclopropanes; Neuroprotectants; Nootropics; Oxadiazoles; Small molecules
  • Mechanism of Action Lysine specific demethylase 1 inhibitors; Monoamine oxidase B inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase II Aggression; Alzheimer's disease; Borderline personality disorders; Multiple sclerosis; SARS-CoV-2 acute respiratory disease; Schizophrenia
  • No development reported Autistic disorder; Dementia; Huntington's disease; Parkinson's disease; Telomeric 22q13 Monosomy Syndrome

Most Recent Events

  • 02 Dec 2024 Oryzon Genomics has received decision to grant communication from the Russian Patent Office for patent application related to vafidemstat, in Russia
  • 01 Oct 2024 ORYZON receives minutes from End-of-Phase II meeting with the US FDA on the phase III PORTICO-2 trial in Borderline personality disorder
  • 23 Sep 2024 Oryzon Genomics hold an end-of-Phase II meeting with the US FDA to discuss plans for the registrational phase III PORTICO-2 trial for Borderline personality disorder

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top